Evidence map›Paper›PMID 26932435›Full record

ArticleChinese clinical oncology2016

Statistical aspect of translational and correlative studies in clinical trials.

Herbert Pang, Xiaofei Wang

Abstract read
In one paragraph

Article in Chinese clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Herbert PangSchool of Public Health, Li Ka Shing Faculty of Medicine, Pok Fu Lam, Hong Kong SAR, China. pathwayrf@gmail.com.
Xiaofei WangDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA. xiaofei.wang@duke.edu.

Funding

Statistical Methods for Cancer Clinical TrialsP01CA142538 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVIDIAN, MARIE, KOSOROK, MICHAEL R · 2010 to 2019
$21.3M
Translational meta-analysis for elderly lung cancer patientsR21AG042894 · NIA · DUKE UNIVERSITY · PI PANG, HERBERT, WANG, XIAOFEI · 2013 to 2014
$373k
NCI NIH HHS P01 CA142538NCI NIH HHS P01CA142538NIA NIH HHS R21 AG042894
6 · The paper itself

Abstract

In this article, we describe statistical issues related to the conduct of translational and correlative studies in cancer clinical trials. In the era of personalized medicine, proper biomarker discovery and validation is crucial for producing groundbreaking research. In order to carry out the framework outlined in this article, a team effort between oncologists and statisticians is the key for success.

Indexed as

Multicenter Studies as TopicResearch DesignTranslational Research, BiomedicalBiomarkers, TumorClinical Trials as TopicHumansNeoplasmsPrognosisBiomarkers, TumorBig databioinformaticsbiomarkersoncologypersonalized medicinetranslational science

Identifiers

PMID26932435
PMCPMC4780353

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.